Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Westby

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Ophthalmology. Retina|May 4, 2019
Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United StatesThomas A Ciulla, Forbes Huang, Keith Westby, et al.
Ophthalmology|October 3, 2021
ReplyGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Ophthalmology|September 4, 2020
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 TrialGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Ophthalmology|February 8, 2021
ReplyGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Eye (London, England)|March 25, 2023
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Eye (London, England)|May 26, 2023
Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Ophthalmology|December 29, 2016
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled TrialGlenn J Jaffe, Thomas A Ciulla, Antonio P Ciardella, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Ophthalmology. Retina|May 4, 2019
Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United StatesThomas A Ciulla, Forbes Huang, Keith Westby, et al.
Ophthalmology|October 3, 2021
ReplyGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Ophthalmology|September 4, 2020
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 TrialGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Ophthalmology|February 8, 2021
ReplyGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Eye (London, England)|March 25, 2023
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Eye (London, England)|May 26, 2023
Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Ophthalmology|December 29, 2016
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled TrialGlenn J Jaffe, Thomas A Ciulla, Antonio P Ciardella, et al.
Pageof 1